Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities

Next Previous
Trial Profile

A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceftaroline fosamil (Primary) ; Aztreonam; Vancomycin
  • Indications Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Acronyms COVERS
  • Sponsors AstraZeneca

    • Most Recent Events

    • 21 Apr 2020 Results of exploratory analysis evaluating the impact of underlying comorbidities on clinical outcomes in patients with cSSTI pooled from these three studies presented at the 30th European Congress of Clinical Microbiology and Infectious Diseases
    • 16 Apr 2019 Results of exploratory analysis evaluating patient characteristics and outcomes among those admitted to the intensive care unit presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
    • 28 Dec 2018 Results assessing safety and tolerability of ceftaroline fosamil q8h and q12h regimens using data from 6 phase three trials (NCT01499277, NCT00424190, NCT00423657, NCT01371838, NCT00621504 and NCT00509106) published in the Journal of Antimicrobial Chemotherapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top